Richard A. Larson to Multicenter Studies as Topic
This is a "connection" page, showing publications Richard A. Larson has written about Multicenter Studies as Topic.
Connection Strength
0.273
-
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncol. 2022 Dec; 18(38):4161-4170.
Score: 0.052
-
Current use and future development of gemtuzumab ozogamicin. Semin Hematol. 2001 Jul; 38(3 Suppl 6):24-31.
Score: 0.047
-
Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol Oncol Clin North Am. 2000 Dec; 14(6):1367-79, x.
Score: 0.045
-
Long-term follow-up of Cancer and Leukemia Group B studies in acute myeloid leukemia. Cancer. 1997 Dec 01; 80(11 Suppl):2210-4.
Score: 0.037
-
Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. Cancer. 2016 07 15; 122(14):2178-85.
Score: 0.033
-
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. J Clin Oncol. 2013 Feb 01; 31(4):440-7.
Score: 0.026
-
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006 Aug 20; 24(24):3895-903.
Score: 0.017
-
A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia. 2006 Jul; 20(7):1295-7.
Score: 0.016